{"nctId":"NCT03067441","briefTitle":"Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)","startDateStruct":{"date":"2017-02-03","type":"ACTUAL"},"conditions":["Hypercholesterolemia","Atherosclerotic Cardiovascular Disease"],"count":1462,"armGroups":[{"label":"Open-Label bempedoic acid","type":"EXPERIMENTAL","interventionNames":["Drug: bempedoic acid"]}],"interventions":[{"name":"bempedoic acid","otherNames":["ETC-1002"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Successfully completed CLEAR Harmony (1002-040) parent study\n\nExclusion Criteria:\n\n* Experienced a treatment-related SAE that led to study drug discontinuation in the CLEAR Harmony (1002-040) parent study.\n* Medical condition requires lipid measurement and/or adjustment of background lipid-regulating therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"385","spread":null},{"groupId":"OG001","value":"758","spread":null},{"groupId":"OG002","value":"1143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"202","spread":null},{"groupId":"OG002","value":"299","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"195","spread":null},{"groupId":"OG002","value":"288","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"403","spread":null},{"groupId":"OG002","value":"614","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"160","spread":null},{"groupId":"OG002","value":"241","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Parent Study Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.82","spread":"23.419"},{"groupId":"OG001","value":"-13.80","spread":"25.018"},{"groupId":"OG002","value":"-13.47","spread":"24.485"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.99","spread":"23.660"},{"groupId":"OG001","value":"-14.15","spread":"25.113"},{"groupId":"OG002","value":"-14.43","spread":"24.632"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Parent Study Baseline in LDL-C at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean Parent Study Baseline value. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.08","spread":"24.995"},{"groupId":"OG001","value":"-15.77","spread":"28.123"},{"groupId":"OG002","value":"-15.19","spread":"27.109"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.11","spread":"25.628"},{"groupId":"OG001","value":"-16.04","spread":"28.929"},{"groupId":"OG002","value":"-16.06","spread":"27.862"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Parent Study Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.60","spread":"20.722"},{"groupId":"OG001","value":"-10.55","spread":"22.682"},{"groupId":"OG002","value":"-10.57","spread":"22.033"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.50","spread":"22.081"},{"groupId":"OG001","value":"-10.82","spread":"23.910"},{"groupId":"OG002","value":"-11.38","spread":"23.321"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Parent Study Baseline in Total Cholesterol at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total cholesterol value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.01","spread":"15.961"},{"groupId":"OG001","value":"-9.79","spread":"16.893"},{"groupId":"OG002","value":"-9.53","spread":"16.582"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.15","spread":"16.541"},{"groupId":"OG001","value":"-9.34","spread":"18.030"},{"groupId":"OG002","value":"-9.61","spread":"17.545"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Parent Study Baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"20.52"},{"groupId":"OG001","value":"-8.8","spread":"21.89"},{"groupId":"OG002","value":"-8.4","spread":"21.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"22.15"},{"groupId":"OG001","value":"-7.0","spread":"22.33"},{"groupId":"OG002","value":"-7.2","spread":"22.26"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Parent Study Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.553","spread":null},{"groupId":"OG001","value":"-19.709","spread":null},{"groupId":"OG002","value":"-16.476","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.005","spread":null},{"groupId":"OG001","value":"-18.065","spread":null},{"groupId":"OG002","value":"-16.740","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Parent Study Baseline in Triglycerides at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.31","spread":null},{"groupId":"OG001","value":"-3.21","spread":null},{"groupId":"OG002","value":"-3.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.00","spread":null},{"groupId":"OG001","value":"-2.60","spread":null},{"groupId":"OG002","value":"-3.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Parent Study Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus Parent Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the mean of the values at screening and predose Day 1/Week 0 (Visit T1) in the Parent Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.54","spread":"16.747"},{"groupId":"OG001","value":"-7.06","spread":"15.638"},{"groupId":"OG002","value":"-6.20","spread":"16.060"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.42","spread":"17.555"},{"groupId":"OG001","value":"-4.91","spread":"16.731"},{"groupId":"OG002","value":"-4.41","spread":"17.018"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Open-Label Extension (OLE) Study Baseline in LDL-C at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: LDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by Parent Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":"23.79"},{"groupId":"OG001","value":"3.6","spread":"27.49"},{"groupId":"OG002","value":"-1.8","spread":"27.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":"25.79"},{"groupId":"OG001","value":"3.7","spread":"30.63"},{"groupId":"OG002","value":"-2.3","spread":"30.31"}]}]}]},{"type":"SECONDARY","title":"Mean Change From OLE Baseline in LDL-C at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Mean change from Baseline was calculated as: Mean LDL-C value at Week 52/Week 78 minus Mean OLE Study Baseline value. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.7","spread":"25.63"},{"groupId":"OG001","value":"0.6","spread":"24.92"},{"groupId":"OG002","value":"-4.6","spread":"26.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.0","spread":"28.56"},{"groupId":"OG001","value":"0.2","spread":"26.04"},{"groupId":"OG002","value":"-5.5","spread":"28.08"}]}]}]},{"type":"SECONDARY","title":"Percent Change From OLE Baseline in Non-HDL-C at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: non-HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"20.81"},{"groupId":"OG001","value":"2.9","spread":"23.98"},{"groupId":"OG002","value":"-1.4","spread":"23.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.8","spread":"23.08"},{"groupId":"OG001","value":"3.1","spread":"28.02"},{"groupId":"OG002","value":"-1.9","spread":"27.38"}]}]}]},{"type":"SECONDARY","title":"Percent Change From OLE Baseline in Total Cholesterol at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Total Cholesterol value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"15.78"},{"groupId":"OG001","value":"1.3","spread":"17.23"},{"groupId":"OG002","value":"-2.1","spread":"17.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"17.39"},{"groupId":"OG001","value":"2.1","spread":"19.88"},{"groupId":"OG002","value":"-1.8","spread":"19.88"}]}]}]},{"type":"SECONDARY","title":"Percent Change From OLE Baseline ApoB at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: ApoB value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"19.94"},{"groupId":"OG001","value":"0.2","spread":"21.48"},{"groupId":"OG002","value":"-3.2","spread":"21.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.2","spread":"21.84"},{"groupId":"OG001","value":"2.4","spread":"23.16"},{"groupId":"OG002","value":"-1.8","spread":"23.49"}]}]}]},{"type":"SECONDARY","title":"Percent Change From OLE Baseline in Hs-CRP at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: hs-CRP value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.720","spread":null},{"groupId":"OG001","value":"-2.174","spread":null},{"groupId":"OG002","value":"-4.856","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.953","spread":null},{"groupId":"OG001","value":"3.774","spread":null},{"groupId":"OG002","value":"-2.538","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From OLE Baseline in Triglycerides at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: Triglycerides value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From OLE Baseline in HDL-C at Weeks 52 and 78","description":"Blood samples were drawn after a minimum 10-hour fast at pre-specified intervals. Percent change from Baseline was calculated as: HDL-C value at Week 52/Week 78 minus OLE Study Baseline value divided by OLE Study Baseline value multiplied by 100. Baseline was defined as the last non-missing record prior to treatment start in the OLE Study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"18.36"},{"groupId":"OG001","value":"-0.6","spread":"14.88"},{"groupId":"OG002","value":"-1.8","spread":"16.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"17.77"},{"groupId":"OG001","value":"2.7","spread":"23.60"},{"groupId":"OG002","value":"0.7","spread":"22.01"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":97,"n":492},"commonTop":["Nasopharyngitis","Urinary tract infection","Arthralgia","Upper respiratory tract infection"]}}}